Ebrotidine

Ebrotidine

Systematic (IUPAC) name
N-(4-bromophenyl)sulfonyl-N'-[2-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]methanimidamide
Clinical data
Routes of administration	Oral
Identifiers
CAS Number	100981-43-9 Y
PubChem	CID: 65869
ChemSpider	59279 N
UNII	TMZ3IBW2OW Y
ChEMBL	CHEMBL1742471
Chemical data
Formula	C14H17BrN6O2S3
Molecular mass	477.42 g/mol
SMILES Brc1ccc(cc1)S(=O)(=O)N/C=N/CCSCc2nc(/N=C(/N)N)sc2
InChI InChI=1S/C14H17BrN6O2S3/c15-10-1-3-12(4-2-10)26(22,23)19-9-18-5-6-24-7-11-8-25-14(20-11)21-13(16)17/h1-4,8-9H,5-7H2,(H,18,19)(H4,16,17,20,21) N Key:ZQHFZHPUZXNPMF-UHFFFAOYSA-N N
NY (what is this?)  (verify)

Ebrotidine is an H₂ receptor antagonist with gastroprotective activity against ethanol-, aspirin- or stress-induced gastric mucosal damage. The antisecretory properties of ebrotidine are similar to those of ranitidine, and approximately 10-fold greater than those of cimetidine. Ebrotidine has anti-Helicobacter pylori activity via inhibition of the urease enzyme and the proteolytic and mucolytic activities of the bacterium. However, its activity is synergistic with a number of antibacterial agents. Ebrotidine counteracts the inhibitory effects of H. pylori lipopolysaccharides.

Ebrotidine has been shown to be as effective as ranitidine for the treatment of gastric or duodenal ulcers or erosive reflux oesophagitis, with significantly better ulcer healing rates (albeit inexplicably) in those who smoke.